Compare Charles River Laboratories Intl. Inc (CRL) vs Gogoro Inc (GGR) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Charles River Laboratories Intl. Inc vs Gogoro Inc — how do they compare? Charles River Laboratories Intl. Inc trades at $227.69 (market cap $11.14B), while Gogoro Inc trades at $3.86 (market cap $76.98M). The key difference: Charles River Laboratories Intl. Inc is far larger — about 144.7× Gogoro Inc's market cap, and Charles River Laboratories Intl. Inc is trading nearer its 52-week high, Gogoro Inc nearer its low. Which is the better fit depends on your goals.
| CRL | GGR | |
|---|---|---|
Market Cap | $11.14B | $76.98M |
Sector | Health | Technology |
52-Week High | $233.60 | $7.89 |
52-Week Low | $145.57 | $2.74 |
Enterprise Value | $14.00B | $379.42M |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Charles River Laboratories (CRL) trades at $229.75, down 1.57% on the day, near its consensus price target of $229.80. The stock shows a bullish technical trend with strong moving average signals and support at $225. Fundamentally, CRL has beaten EPS estimates for three consecutive quarters but reported a net loss of $144.34 million in 2025, with negative profit margins. Recent news highlights collaborations in AI and NGS services, supporting growth prospects.
Outlook remains mixed: analyst consensus is strongly bullish with 72% buy ratings and a high target of $260, but profitability challenges and high P/E of 684.85 pose risks. Cash flow stability and strategic partnerships offer upside, while margin pressures and debt levels require monitoring for sustained recovery.
GGR trades at $3.88, up 0.78% on the day, while showing bearish technical signals with a negative net income margin of -24.68% and ROE of -50.38% for 2025. The company reported revenue of $281.48M but a net loss of $79.97M, though cash flow from operations improved to $35.90M. Recent news highlights a private placement and Q1 2026 results emphasizing margin improvement and growth plans.
Outlook remains challenged by persistent losses and negative profitability metrics, offset by operational discipline and subscriber growth. Key risks include execution on profitability, competitive pressures, and cash flow sustainability. Analysts are neutral with 100% hold ratings, reflecting cautious optimism amid fundamental headwinds.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Charles River Laboratories Intl. Inc
Charles River Laboratories was founded in 1947 and is a leading provider of drug discovery and development services. The company's research model & services segment is the leading provider of animal models for laboratory testing, which breeds and delivers animal research models with specific genetic characteristics for preclinical studies around the world. The discovery & safety assessment segment includes services required to take a drug through the early development process, including discovery services. The manufacturing support segment includes microbial solutions, which provides in vitro (non-animal) testing products, biologics testing services, and avian vaccine services.
Read more on CRL →About Gogoro Inc
Gogoro is a global technology leader in battery-swapping ecosystems for electric two-wheelers. It provides smart, sustainable urban mobility solutions and manages an extensive network of battery stations.
Read more on GGR →
